Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes.
- Author:
Hui-Li ZHU
1
;
Rui-Min YU
;
Xin-Zhi HUANG
;
Wei HUANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; C-Reactive Protein; metabolism; Diabetes Mellitus, Type 2; blood; complications; drug therapy; Female; Humans; Hypoglycemic Agents; therapeutic use; Inflammation; blood; prevention & control; Insulin Resistance; Interleukin-1beta; blood; Interleukin-6; blood; Male; Middle Aged; Obesity; complications; Thiazolidinediones; therapeutic use; Tumor Necrosis Factor-alpha; blood
- From: Journal of Southern Medical University 2008;28(6):1050-1051
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the effect of rosiglitazone on serum high-sensitivity C-reactive protein (hs-CRP), interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha) and insulin resistance in obese patients with newly diagnosed type 2 diabetes.
METHODSThis study involved 118 patients with newly diagnosed type 2 diabetes and obesity, who were randomly assigned into two groups for a 12-week treatment with rosiglitazone (4 mg/day, group A) or sulfonylureas (group B). Serum hs-CRP, IL-1beta, IL-6, TNF-alpha, fasting plasma glucose (FPG) and fasting insulin (FINS) were measured before and after the treatment. Insulin resistance index was calculated according to the HOMA Model.
RESULTSIn group A, rosiglitazone treatment resulted in significantly reduced serum hs-CRP, IL-1beta, IL-6, TNF-alpha, FPG and insulin resistance index (P<0.01). No difference in FPG was found between the two groups after the treatment (P>0.05), but serum hs-CRP, IL-1beta, IL-6, TNF-alpha and insulin resistance index were significantly lower in group A than in group B (P<0.05).
CONCLUSIONRosiglitazone can decrease FPG, reduce the inflammation reaction and improve insulin resistance in obese patients with type 2 diabetes.
